The WHO (World Health Organization) Collaborating Centre for Healthy Ageing and Dementia at Hamad Medical Corporation (HMC) in Qatar, in collaboration with the WHO, will be hosting an International Workshop on Evidence-Based Policy Development and Health System Preparedness for Future Pandemics in Ageing Populations. The event will be held this Sunday 28th September in Doha and online.
This high-level workshop, under the leadership of Prof. Hanadi Al Hamad, will bring together international experts, policymakers, healthcare leaders, and community stakeholders to share evidence, strengthen health system resilience, and co-develop actionable recommendations that support the goals of the WHO Decade of Healthy Ageing (2021–2030). Bournemouth University contribution is through Professor Edwin van Teijlingen from the Centre for Midwifery & Women’s Health (CMWH). He will be facilitating an online workshop on “Identifying Priority Actions and Recommendations on Policy & Programme Implications”. To celebrate Bournemouth University’s long-term collaboration with Hamad Medical Corporation (a not-for-profit organisation in Qatar), GlobalBU is in the process of signing a Memorandum of Agreement with HMC.
Research methods training in Qatar
COVID-19 in Qatar










BU Prof Jonathan Parker promoting social work in Malaysia
New interdisciplinary paper accepted for publication
Three NIHR Internships awarded at BU
Research highlighted at the UN in New York
Poverty in the UK: book launch today at BU
BU contributions to successful Global Health conference
Horizon Europe Cluster 3 (Civil Security for Society) 2026 Calls Now Open
MSCA Doctoral Networks 2026 Call Information Webinar
ESRC Festival of Social Science 2026: Application Deadline Extended to Thursday 25 June 2026
Reminder: Register for the ESRC Festival of Social Science 2026 Information Session
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease